Working… Menu

Hydralazine Valproate for Cervical Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00532818
Recruitment Status : Unknown
Verified March 2009 by National Institute of Cancerología.
Recruitment status was:  Recruiting
First Posted : September 20, 2007
Last Update Posted : March 30, 2009
Psicofarma S.A. de C.V.
Information provided by:
National Institute of Cancerología

Brief Summary:

The current standard for recurrent, persistent or metastatic cervical cancer is palliative chemotherapy with cisplatin topotecan, however, the results need to be improved. Epigenetic aberrations play an important role in cancer progression by silencing growth regulatory genes and there is now evidence that inhibitors of DNA methylation and HDAC inhibition synergize the cytotoxicity of chemotherapy.

Objective. To determine the superiority of epigenetic therapy with hydralazine and valproate plus standard cisplatin topotecan against placebo plus cisplatin topotecan upon progression-free survival.

Hypothesis. Hydralazine and magnesium valproate associated to cisplatin topotecan will increase progression-free survival from 4.6 to 7.6 months as compared with the same regimen of chemotherapy plus placebo.

Condition or disease Intervention/treatment Phase
Metastatic Cervical Cancer Drug: Hydralazine and magnesium valproate Drug: Placebo Phase 3

Detailed Description:
Randomized, double-blind phase III trial. A total of 143 patients (alpha 0.5, power 0.8)with metastatic, persistent or recurrent cervical cancer without previous systemic treatment will be randomized to cisplatin topotecan + placebo or cisplatin topotecan hydralazine valproate for 6 courses every 3 weeks. Patients will receive an oral dose of hydralazine of 182mg (rapid) or 83mg (slow) according to the acetylator phenotype in a single daily dose and magnesium valproate at an oral dose of 40mg/Kg t.i.d. Both drugs in a slow-release formulation. Experimental drugs or placebo will start from seven days before day 1 of chemotherapy until the end of the sixth course.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 143 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized, Double-Blind, Phase III Trial of Chemotherapy Plus the Transcriptional Therapy Hydralazine and Magnesium Valproate Versus Chemotherapy Plus Placebo in Recurrent and Metastatic Cervical Cancer.
Study Start Date : July 2007
Estimated Primary Completion Date : September 2010
Estimated Study Completion Date : December 2010

Arm Intervention/treatment
Placebo Comparator: 1 Drug: Placebo
Cisplatin + Topotecan plus placebo

Experimental: 2 Drug: Hydralazine and magnesium valproate
Cisplatin + Topotecan plus hydralazine valproate

Primary Outcome Measures :
  1. Progression-free survival [ Time Frame: 2-years ]

Secondary Outcome Measures :
  1. Response rate, safety, overall survival. [ Time Frame: 2-years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • informed consent, histological diagnosis of persistent, recurrent or metastatic cervical carcinoma; measurable disease by physical examination, CT Scan, MRI or PET-CT. Biopsy is required for confirmation only if the lesion is unique, has less than 2cm in the longest diameter or has no clearly defined borders.
  • Patients should have no previous systemic treatment (could have received chemotherapy as radiosensitization to the pelvis and or para-aortic field.
  • Aged >18 years, performance status 0-2 according to ECOG classification, and adequate liver, hematological and renal function, as defined by: hemoglobin >10 g/L, leukocytes >4000/mm3, platelets >100 000mm3; normal creatinine value and creatinine clearance >60 mL/min; total bilirubin < 1.5 upper normal limit value.

Exclusion Criteria:

  • History of allergy to hydralazine or valproate; past or present condition of rheumatic disease, central nervous system disease, heart failure from aortic stenosis and postural hypotension as diagnosed by a physician; newly diagnosed hypertension patients with or without pharmacological treatment are allowed as long as their treatment do not include hydralazine.
  • Previous use of the experimental drugs (hydralazine and magnesium valproate) as well as if patients were pregnant or breast-feeding. Other exclusion criteria are uncontrolled systemic disease or infection.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00532818

Layout table for location contacts
Contact: Alfonso Dueñas-Gonzalez, MD PhD +5255 56280486

Layout table for location information
Instituto Nacional de Cancerologia Recruiting
Mexico City, Distrito Federal, Mexico, 14080
Principal Investigator: Lucely Cetina, MD         
Sponsors and Collaborators
National Institute of Cancerología
Psicofarma S.A. de C.V.
Layout table for investigator information
Study Chair: Myrna Candelaria, MD Instituto Nacional de Cancerologia, Columbia

Additional Information:
Layout table for additonal information
Responsible Party: Lucely Cetina, Instituto Nacional de Cancerologia Identifier: NCT00532818     History of Changes
Other Study ID Numbers: 006/027/ICI
First Posted: September 20, 2007    Key Record Dates
Last Update Posted: March 30, 2009
Last Verified: March 2009
Keywords provided by National Institute of Cancerología:
Epigenetic therapy
Cervical cancer
Phase III
Additional relevant MeSH terms:
Layout table for MeSH terms
Uterine Cervical Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female
Valproic Acid
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
GABA Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Antimanic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Antihypertensive Agents
Vasodilator Agents